June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Incidence of Second Primary Malignancy in Primary Optic Nerve Glioma: A US National Database Analysis
Author Affiliations & Notes
  • Jawad Khan
    Texas Tech University Health Sciences Center El Paso Paul L Foster School of Medicine, El Paso, Texas, United States
  • Zain Hussain
    Texas Tech University Health Sciences Center El Paso Paul L Foster School of Medicine, El Paso, Texas, United States
  • Fatma Dihowm
    Texas Tech University Health Sciences Center El Paso Paul L Foster School of Medicine, El Paso, Texas, United States
  • Footnotes
    Commercial Relationships   Jawad Khan, None; Zain Hussain, None; Fatma Dihowm, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2853. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jawad Khan, Zain Hussain, Fatma Dihowm; Incidence of Second Primary Malignancy in Primary Optic Nerve Glioma: A US National Database Analysis. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2853.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Advanced understanding of screening and therapeutic modalities acts as provision for increased survival in patients diagnosed with optic nerve gliomas. Second primary malignancies (SPM) and latency periods is currently an uncharacterized frontier. This US national database analysis showcases incidences of SPMs and latency periods in patients with optic nerve gliomas.

Methods : The Surveillance, Epidemiology, and End Results (SEER) database was executed for procurement of nationally de-identified cases of first primary optic nerve glioma. Standardized incidence ratios (SIR) and excess absolute risk (EAR) were calculated using the SEER-specific multiple outcome analysis. 95% SIR confidence intervals are demonstrated with statistical significance achieved at p < 0.05.

Results : 622 patients with primary optic nerve glioma were selected. Mean age was 14.6±19 years (range 00–80). 315 (50.6%) patients and 307 (49.4%) patients were female and male, respectively. Relative to the US national population, patients afflicted with primary optic nerve gliomas demonstrated significantly increased risk for multiple SPMs. Primary malignancies originating from soft tissues (including the heart) (SIR 33.2, CI 6.9–97.1, EAR 5.1), breast (SIR 4.99, CI 1.4–12.8, EAR 5.6), female breast (SIR 5.0, CI 1.4–12.9, EAR 5.6), brain (SIR 105.4, CI 65.2–161.1, EAR 36.2), cranial nerves (SIR 103.3, CI 12.5–373.1, EAR 3.5), non-lymphocytic leukemia (SIR 15.6, CI 1.9–54.4, EAR 3.3), myeloid and monocytic leukemia (SIR 16.3, CI 1.97–58.8, EAR 3.3), and Kaposi sarcoma (SIR 79.9, CI 2.0–445.1, EAR 1.7) demonstrated significantly increased SIR as SPMs as showcased in Table 1. In totality, cumulative SPM (SIR 6.04, CI 4.3–8.2, EAR 59.6) showcases overall significance in incidence rates of SPM in patients diagnosed with optic nerve gliomas.

Conclusions : As compared to the US national population, diagnosis of first primary optic nerve gliomas prognosticates increased chances for formation of second primary malignancies, including tumors of all sites, soft-tissue, brain, cranial nerve, non-lymphocytic leukemia, myeloid and monocytic leukemia and Kaposi’s sarcoma. Advancements related to diagnosis and treatment modalities may sustain survival. Yet, some treatments may increase incidence of malignancies. Clinical decision-making should reconcile enhanced propensities for development of second primary malignancies.

This is a 2021 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×